Want to see VRDN full AI Analyst Report?
VRDN Stock Chart & Stats
$24.18
<$0.01(0.05%)
At close: 4:00 PM EDT
$24.18
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$13.18 - $34.29
Previous Close$19.2
Volume1.52M
Average Volume (3M)1.48M
Market Cap
$2.32B
Enterprise Value$1.34K
Total Cash (Recent Filing)$981.53M
Total Debt (Recent Filing)$242.88M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 16, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding113,292,270
10 Day Avg. Volume2,119,576
30 Day Avg. Volume1,480,287
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)3.65
Price to Sales (P/S)37.25
P/FCF Ratio-9.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.70Price Target Upside39.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.93
Revenue Forecast (FY)$21.69M
Bulls Say, Bears Say
Bulls Say
Revenue ExpansionThe sharp revenue increase from the historically small base indicates meaningful progress in advancing Viridian’s programs and generating business activity. Sustaining this trajectory could improve future commercial potential, support operating leverage, and strengthen the company’s position as its pipeline develops.
Low Leverage And Sizable EquityA sizable equity base combined with low leverage provides financial flexibility for a development-stage biotechnology company. This structure can support continued research and clinical execution while reducing the immediate pressure that heavier debt obligations would place on capital allocation.
Funding And Execution ReadinessRecent financing and full repayment of the Hercules loan improve funding flexibility and reduce future financing obligations. The WuXi manufacturing agreement also supports potential commercialization readiness, giving Viridian greater infrastructure to advance programs toward later-stage development.
Bears Say
Persistent Operating LossesLarge and persistent losses show that Viridian’s current activities require substantial investment without yet producing sustainable profitability. Continued heavy operating expenses could delay breakeven, consume capital needed for development, and make future earnings dependent on successful pipeline advancement.
Substantial Cash BurnDeeply negative operating and free cash flow indicate that the business is not self-funding and requires substantial external capital to continue operations. Persistent cash burn can increase financing dependence and reduce flexibility if clinical programs take longer or require more investment.
No Approved Recurring Product RevenueAs a clinical-stage biotechnology company without an approved commercial product, Viridian lacks an established recurring product-sales base. Future revenue depends on clinical progress, regulatory approval, and commercialization, while ongoing operations remain exposed to continued financing needs.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $13.18 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $2.32B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 49 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Aug 06, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$1.035 by -$0.015.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -0.99.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 113,292,270 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$1.035. Following the earnings report the stock price went up 6.834%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Currently, no hedge funds are holding shares in VRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.70 (39.37% Upside)
$33.70 (39.37% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 60%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Increased
By 957.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $348.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
88.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Viridian Therapeutics
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
VRDN Stock 12 Month Forecast
Average Price Target
$33.70
▲(39.37% Upside)
Technical Analysis
Celldex
―
Ultragenyx Pharmaceutical
―
MoonLake Immunotherapeutics
―
Vera Therapeutics
―
Zenas BioPharma, Inc.
―
Ownership Overview
4.58% Insiders
25.59% Mutual Funds
52.74% Other Institutional Investors
2.38% Public Companies and
Individual Investors